3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
6
Colorectal Neoplasms
4
Lung Neoplasms
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Pain
2
Motor Activity
2
Hematopoietic and Lymphatic System Neoplasm
2
Carcinoma, Non-Small-Cell Lung
2
Breast Carcinoma In Situ
2
Squamous Cell Carcinoma of Head and Neck
1
Smoking Cessation
1
Sedentary Behavior
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Pulmonary Disease, Chronic Obstructive
1
Polyps
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Metastatic Pancreatic Adenocarcinoma
1
Malignant Hepatobiliary Neoplasm
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Insulin Resistance
1
Hodgkin Disease
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
29
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Radiotherapy
14
Nivolumab
12
Ramucirumab
11
Cyclophosphamide
11
Trastuzumab
8
Erlotinib Hydrochloride
8
Taxes
7
Radiosurgery
7
Drug Therapy
7
cemiplimab
6
zolbetuximab
5
trastuzumab deruxtecan
5
regorafenib
5
durvalumab
5
Sorafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma
×
Telemedicine
×
Clear all
NCT04667403
2022-04-28
PANTELO
Institut Cancerologie de l'Ouest
Phase NA
Unknown
50 enrolled